CA2903869A1 - Apolipoprotein e dosing regimen for treating atherosclerosis - Google Patents

Apolipoprotein e dosing regimen for treating atherosclerosis Download PDF

Info

Publication number
CA2903869A1
CA2903869A1 CA2903869A CA2903869A CA2903869A1 CA 2903869 A1 CA2903869 A1 CA 2903869A1 CA 2903869 A CA2903869 A CA 2903869A CA 2903869 A CA2903869 A CA 2903869A CA 2903869 A1 CA2903869 A1 CA 2903869A1
Authority
CA
Canada
Prior art keywords
seq
apo
mimetic
rev
treatment cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2903869A
Other languages
English (en)
French (fr)
Inventor
G. M. Anantharamaiah
Dennis Goldberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
LipimetiX Development LLC
Original Assignee
UAB Research Foundation
LipimetiX Development LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation, LipimetiX Development LLC filed Critical UAB Research Foundation
Publication of CA2903869A1 publication Critical patent/CA2903869A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA2903869A 2013-03-14 2014-03-14 Apolipoprotein e dosing regimen for treating atherosclerosis Abandoned CA2903869A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361782956P 2013-03-14 2013-03-14
US61/782,956 2013-03-14
US201361834992P 2013-06-14 2013-06-14
US61/834,992 2013-06-14
PCT/US2014/027719 WO2014152776A1 (en) 2013-03-14 2014-03-14 Apolipoprotein mimetics and uses thereof

Publications (1)

Publication Number Publication Date
CA2903869A1 true CA2903869A1 (en) 2014-09-25

Family

ID=51581312

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2903869A Abandoned CA2903869A1 (en) 2013-03-14 2014-03-14 Apolipoprotein e dosing regimen for treating atherosclerosis

Country Status (12)

Country Link
US (1) US20160002315A1 (cg-RX-API-DMAC7.html)
EP (1) EP2996706B1 (cg-RX-API-DMAC7.html)
JP (2) JP6570511B2 (cg-RX-API-DMAC7.html)
AU (2) AU2014239186B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015022624A2 (cg-RX-API-DMAC7.html)
CA (1) CA2903869A1 (cg-RX-API-DMAC7.html)
DK (1) DK2996706T3 (cg-RX-API-DMAC7.html)
ES (1) ES2753381T3 (cg-RX-API-DMAC7.html)
IL (1) IL240787B (cg-RX-API-DMAC7.html)
MX (1) MX2015012818A (cg-RX-API-DMAC7.html)
NZ (1) NZ713291A (cg-RX-API-DMAC7.html)
WO (1) WO2014152776A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3189069B1 (en) 2014-07-31 2024-10-23 UAB Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
WO2017120568A1 (en) * 2016-01-08 2017-07-13 Lipimetix Development, Inc. Apoe mimetic peptide compositions
IL260931B2 (en) * 2016-02-17 2024-09-01 Regeneron Pharma Methods of treating or preventing atherosclerosis by blocking ANGPTL3
WO2017151783A1 (en) 2016-03-03 2017-09-08 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
EP4384199A4 (en) * 2021-08-11 2025-07-02 The Regents Of Univ Of California PEPTIDES FOR MEMBRANES RETAINING A BARRIER FUNCTION

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5631280A (en) 1995-03-29 1997-05-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6506880B2 (en) 1998-03-17 2003-01-14 The Uab Research Foundation Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2521564B1 (en) * 2010-01-06 2016-11-16 Cognosci, Inc. Apoe peptide dimers and uses thereof
EP3189069B1 (en) * 2014-07-31 2024-10-23 UAB Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol

Also Published As

Publication number Publication date
AU2017203911B2 (en) 2019-03-07
ES2753381T3 (es) 2020-04-08
MX2015012818A (es) 2016-05-12
EP2996706A1 (en) 2016-03-23
BR112015022624A2 (pt) 2017-10-31
AU2017203911A1 (en) 2017-06-29
JP2016515137A (ja) 2016-05-26
DK2996706T3 (da) 2019-10-21
NZ713291A (en) 2017-04-28
JP6772317B2 (ja) 2020-10-21
EP2996706B1 (en) 2019-07-31
IL240787B (en) 2019-07-31
IL240787A0 (en) 2015-10-29
JP6570511B2 (ja) 2019-09-04
AU2014239186A1 (en) 2015-10-08
JP2019089834A (ja) 2019-06-13
EP2996706A4 (en) 2017-01-18
AU2014239186B2 (en) 2017-04-20
WO2014152776A1 (en) 2014-09-25
US20160002315A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
US10653747B2 (en) ApoE mimetic peptides and higher potency to clear plasma cholesterol
US8048851B2 (en) Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US20100227825A1 (en) Peptides and peptide mimetics to treat cancer
JP6772317B2 (ja) アポリポタンパク質模倣体及びその使用
US20130295042A1 (en) Peptides and Peptide Mimetics to Treat Pathologies Associated With Eye Disease
US20080293639A1 (en) Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US20100240598A1 (en) Peptides and peptide mimetics to inhibit the onset and/or progression of fibrotic and/or pre-fibrotic pathologies
HK1242718B (zh) Apoe模拟肽及对清除血浆胆固醇的较高效力
HK1242718A1 (en) Apoe mimetic peptides and higher potency to clear plasma cholesterol

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150902

FZDE Discontinued

Effective date: 20220407

FZDE Discontinued

Effective date: 20220407